Cargando…
Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia
Pitavastatin was first developed in Japan and is expanding the regions in which it is clinically available. A considerable number of clinical studies have been conducted and published to date on the usefulness of pitavastatin for patients with primary hypercholesterolemia or combined dyslipidemia. P...
Autor principal: | Sasaki, Jun |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988623/ https://www.ncbi.nlm.nih.gov/pubmed/21127702 http://dx.doi.org/10.2147/VHRM.S7802 |
Ejemplares similares
-
Pitavastatin: evidence for its place in treatment of hypercholesterolemia
por: Alagona, Peter
Publicado: (2010) -
Benefit–risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients
por: Chamberlin, Kevin W, et al.
Publicado: (2015) -
Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals
por: Saito, Yasushi
Publicado: (2009) -
Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2009) -
Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe
por: Harada-Shiba, Mariko, et al.
Publicado: (2018)